Evolution Petroleum reported fiscal fourth quarter and full year 2026 results, with Q4 revenue increasing 20% sequentially to $24.2 million and net income rebounding to $4.6 million. The company also declared its 52nd consecutive quarterly dividend of $0.12 per share and highlighted the subsequent $16.0 million acquisition of Permian Basin mineral and royalty interests.
Term
FY2026
Earnings call
Sep 16, 2026, 11:00 AM ET
“Fiscal 2026 was another important year for Evolution as we broadened the portfolio with strategic acquisitions, maintained $0.48 per share in dividends, and increased proved reserves over and above the roughly 2.6 MMBOE we produced during the year. Underpinning our shareholder return strategy is the durability and continued renewal of our asset base.”
Uranium Royalty Corp. reported its Q1 fiscal 2027 results, highlighted by a 1530% increase in net income to $16.3 million and revenue of $51.0 million from the sale of 593,255 pounds of U3O8. The company utilized proceeds from these uranium sales to help finance its Sweetwater acquisition, which closed in July 2026.
Vera Bradley reported second quarter fiscal 2027 consolidated net revenues of $71.6 million, a 1.1% increase year-over-year, driven by 8% growth in its Direct Segment. The company achieved net income of $4.5 million compared to a net loss in the prior year, supported by improved margins and a $7.7 million tariff refund. Management reiterated its full-year sales and operating margin guidance while highlighting a 28% reduction in inventory levels.
Term
Q2 2027
Earnings call
Sep 15, 2026, 8:30 AM ET
“I’m pleased to report that our second quarter results reflect continued momentum in our transformation. This marked our second consecutive quarter of overall revenue growth, with total revenue up 1.1% versus the prior year. The underlying health of our business continued to strengthen across our direct channels, margin structure, and balance sheet.”
Ian Bickley, Chairman and Chief Executive Officer
“Based on our year-to-date performance, we continue to expect year-over-year non-GAAP operating loss improvement of at least 50%. Significant work remains, and we’re encouraged by the progress we’re seeing across all five pillars of our transformation, and we remain committed to returning the business to long-term sustainable growth, profitability, and cash flow generation.”
Forgent Power Solutions reported record fiscal fourth quarter and full year 2026 results, with annual revenue growing 89% to $1.42 billion and net income rising 508% to $106 million. The company ended the year with an all-time high backlog of $3.0 billion and announced a $35 million investment to expand manufacturing capacity in Tijuana, Mexico.
Term
FY2026
Earnings call
Sep 15, 2026, 11:00 AM ET
“Momentum in electrical distribution equipment remains robust, and Forgent’s products and solutions continue to gain traction with customers. We booked more than $1.5 billion of orders in the fourth quarter — an amount that exceeded our total revenue for the full fiscal year — highlighting the strength of our offerings. Our performance demonstrates that Forgent is not only benefiting from industry growth, but also gaining share and significantly outpacing the broader market”
Pharma-Bio Serv reported Q3 2026 revenues of $2.3 million and a net loss of $14,000, representing a $0.4 million revenue increase and a $190,000 bottom-line improvement over the prior year. For the nine months ended July 31, 2026, the company achieved net income of $252,000 on revenues of $7.3 million.
Term
Q3 2026
“Our Q3 results demonstrate the strength of our client relationships and the value of our specialized regulatory and compliance capabilities. By sharpening our focus on markets where our expertise creates a distinct competitive advantage and continuing to drive operating efficiencies, we meaningfully improved our financial performance. We remain confident in our ability to build on this progress and carry that momentum through the final quarter of the year”
Dave & Buster's reported second quarter 2026 revenue of $544.1 million, a 2.4% decrease year-over-year, with comparable store sales down 2.9%. The company swung to a net loss of $12.5 million compared to net income of $11.4 million in the prior year period. Despite the loss, management highlighted momentum in their 'Back-to-Basics' strategy and improved sales trends in July and the early third quarter.
Term
Q2 2026
Earnings call
Sep 14, 2026, 7:00 PM ET
“We are energized by the obvious, actionable, and enormous opportunities ahead for Dave & Buster’s and Main Event. Our Back-to-Basics strategy is gaining momentum with enhanced executional urgency. We are experiencing ongoing growth in food and beverage sales as well as in Special Events sales. The same store sales of our remodels continue to outperform the system. Further, we improved overall same store sales in July, and saw continued improvement in overall same store sales during the third quarter to date. We are laser focused on returning to same-store sales and EBITDA growth, sharpening our margin management with cost saving initiatives, generating significant free cash flow, and delivering meaningful shareholder value. I have tremendous confidence in the direction of our business and am excited about what we will accomplish together as we shape the future of our company.”
Benitec Biopharma reported financial results for the fiscal year ended June 30, 2026, ending the period with approximately $180 million in cash. The company provided a clinical update on its BB-301 program for OPMD-related dysphagia, noting that Cohort 2 is fully enrolled and a pivotal study is planned for initiation in mid-2027 following a Type C meeting with the FDA.
Term
FY2026
“This has been an important year of clinical execution for Benitec and for the continued development of BB-301. Over the course of the year, we completed the follow-up of all six patients in Cohort 1 and fully enrolled Cohort 2, while continuing the regulatory interactions required to prepare BB-301 for advancement into a pivotal trial.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
“The consistency and durability of the clinical benefit observed to date, together with the discussions we have had with the FDA regarding pivotal study plans, continue to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”
Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
Kestra Medical Technologies reported first quarter fiscal 2027 revenue of $31.0 million, a 60% increase year-over-year, driven by wearable cardioverter defibrillator (WCD) market expansion and competitive gains. The company reported a GAAP net loss of $44.1 million and increased its full-year fiscal 2027 revenue guidance to $141 million.
Term
Q1 2027
Earnings call
Sep 14, 2026, 4:30 PM ET
“Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%. We remain confident that our focus on innovation and commercial expansion positions Kestra to generate durable, top-tier growth for years to come. Our team is executing on its commitments to prescribers and their patients and we believe this will continue to drive market expansion and advance Kestra on its path to market leadership.”
Immersion Corporation reported Q1 fiscal 2027 total revenues of $294.4 million and GAAP net income of $4.9 million, or $0.17 per diluted share. The results include the consolidated financial information of Barnes & Noble Education, in which Immersion holds a 32.3% stake. The company also declared its sixteenth consecutive quarterly dividend of $0.075 per share.
Term
Q1 2027
“Our fiscal year is off to a strong start. While financial performance can be lumpy, we continue to be focused on executing against strategic initiatives that will drive long-term shareholder value.”
RF Industries reported record third-quarter fiscal 2026 net sales of $23.96 million, a 21% year-over-year increase. Net income rose 267% to $1.44 million, or $0.12 per diluted share, driven by a shift toward higher-value custom cabling and integrated systems solutions. The company ended the quarter with a backlog of $18.6 million and reported significant margin expansion to 35.6%.
Term
Q3 2026
Earnings call
Sep 14, 2026, 8:30 AM ET
“The RFI team delivered another quarter of accelerating topline growth by converting stronger demand into expanding margins and dramatically higher profitability, as well as demonstrating the earnings power of the business as revenue scales above the $20 million quarterly run rate.”
Robert Dawson, Chief Executive Officer of RF Industries
“Our steady margin expansion is a direct result of successfully executing a multi-year mix shift toward higher-value solutions, including our custom cabling and integrated systems offerings. These solutions have more engineering content, larger project scope, and engender stronger customer relationships than traditional component sales.”
Robert Dawson, Chief Executive Officer of RF Industries
AMREP Corporation reported financial results for its first fiscal quarter ended July 31, 2026, with revenues of $6.1 million compared to $17.9 million in the prior year period. Net income decreased significantly to $276,000, or $0.05 per diluted share, from $4.7 million in the same quarter of the previous year.
National Beverage Corp. reported Q1 2026 net sales of $331 million and earnings per share of $0.50. Results were impacted by elevated aluminum commodity costs and tariffs, which negatively affected gross margin by approximately 600 basis points. The company also highlighted the payment of a $304 million special dividend ($3.25 per share) during the quarter.